Familial Cancer

, Volume 11, Issue 2, pp 279–289

Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore

  • Vivian Wei Wang
  • Poh Koon Koh
  • Wai Leng Chow
  • Jeremy Fung Yen Lim
Original Article

Abstract

Colorectal cancer (CRC) is the most common cancer in Singapore. We sought to evaluate the long-term cost-effectiveness of targeted genetic testing and surveillance programs in individuals at high risk of hereditary non-polyposis colorectal cancer (HNPCC), as compared to an unselective clinical surveillance program alone in Singapore. A Markov model analysis from the healthcare service provider’s perspective was developed to follow over a lifetime a cohort of cancer-free 21-year-old individuals, who were first-degree relatives of HNPCC patients with a known mutation. Genetic testing strategy provided a lifetime saving of Singapore dollars (SGD) 13,588 per person and gained additional life years of 0.01, as compared to clinical surveillance alone, by sparing non-mutation carriers from unnecessary and invasive intensive clinical surveillance (assuming 100% compliance with recommended surveillance programs in both strategies). Sensitivity analyses showed that as long as the compliance rate in mutation carriers was not lower than that for individuals without genetic testing, pursuing a genetic testing strategy would either be a more favorable option with discounted incremental cost-effectiveness ratios ranging from SGD 6,961 to 17,289 per life year gained or a dominant status achieved (more life year gained and less costly). Genetic testing for individuals at high risk of HNPCC allows targeted clinical surveillance to be directed at mutation carriers, ensuring efficient use of healthcare resources and reduces CRC-related mortality. It can be regarded as a cost-effective strategy in Singapore, if an improved compliance with recommended surveillance protocol is achieved in proven mutation carriers.

Keywords

Hereditary non-polyposis colorectal cancer Surveillance Genetic testing Markov modeling Cost-effectiveness 

References

  1. 1.
    National Registry of Diseases Office of Singapore (2011) Singapore cancer registry interim annual registry report: trends in cancer incidence in Singapore 2005–2009 Health Promotion Board Singapore. http://www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer_Trends_Report%20_05-09.pdf. Accessed 1 August 2011
  2. 2.
    Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRefGoogle Scholar
  3. 3.
    Lamberti C, Mangold E, Pagenstecher C et al (2006) Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 74(1):58–67PubMedCrossRefGoogle Scholar
  4. 4.
    Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932PubMedCrossRefGoogle Scholar
  5. 5.
    Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114–1125PubMedCrossRefGoogle Scholar
  6. 6.
    Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677–685PubMedCrossRefGoogle Scholar
  7. 7.
    Watson P, Riley B (2005) The tumor spectrum in the Lynch syndrome. Fam Cancer 4(3):245–248PubMedCrossRefGoogle Scholar
  8. 8.
    Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218PubMedCrossRefGoogle Scholar
  9. 9.
    Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129(2):415–421PubMedGoogle Scholar
  10. 10.
    Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104(5):1535–1549PubMedGoogle Scholar
  11. 11.
    Koh PK, Chew MH, Tan YS et al. (2010) Preliminary results of mismatch repair deficiency screening via immunohistochemical staining in young Asian colorectal cancers. In: Ling KL (ed) Proceedings of Singapore healthcare, vol 19, (1). pp 3–11Google Scholar
  12. 12.
    Ministry of Health Singapore (2010) MOH Clinical Practice Guidelines on cancer screening. http://www.moh.gov.sg/content/dam/moh_web/Publications/Guidelines/Clinical%20practice%20guidelines/2010/cpg_Cancer%20Screening%20Booklet%20FINAL%20v6.pdf. Accessed 1 Aug 2011
  13. 13.
    Stanley AJ, Gaff CL, Aittomaki AK et al (2000) Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). Med J Aust 172(7):313–316PubMedGoogle Scholar
  14. 14.
    Loader S, Shields C, Rowley PT (2005) Impact of genetic counseling and DNA testing on individuals with colorectal cancer with a positive family history: a population-based study. Genet Test 9(4):313–319PubMedCrossRefGoogle Scholar
  15. 15.
    Lynch HT, Watson P, Shaw TG et al (1999) Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: hereditary nonpolyposis colorectal carcinoma as a model. Cancer 86(11 Suppl):2457–2463PubMedCrossRefGoogle Scholar
  16. 16.
    Dinh TA, Rosner BI, Atwood JC et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22Google Scholar
  17. 17.
    Kievit W, de Bruin JH, Adang EM et al (2005) Cost effectiveness of a new strategy to identify HNPCC patients. Gut 54(1):97–102PubMedCrossRefGoogle Scholar
  18. 18.
    Ramsey SD, Burke W, Clarke L (2003) An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 5(5):353–363PubMedCrossRefGoogle Scholar
  19. 19.
    Ramsey SD, Clarke L, Etzioni R et al (2001) Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 135(8 Pt 1):577–588PubMedGoogle Scholar
  20. 20.
    Reyes CM, Allen BA, Terdiman JP, Wilson LS (2002) Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 95(9):1848–1856PubMedCrossRefGoogle Scholar
  21. 21.
    Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129(10):787–796PubMedGoogle Scholar
  22. 22.
    Vasen HF, van Ballegooijen M, Buskens E et al (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82(9):1632–1637PubMedCrossRefGoogle Scholar
  23. 23.
    Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT (2007) Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 23(1):89–95PubMedCrossRefGoogle Scholar
  24. 24.
    Breheny N, Geelhoed E, Goldblatt J, Ee H, O’Leary P (2006) Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Commun Genet 9(2):98–106CrossRefGoogle Scholar
  25. 25.
    Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489–498PubMedCrossRefGoogle Scholar
  26. 26.
    Altekruse SF, Kosary CL, Krapcho M et al. (2010) SEER cancer statistics review 1975–2007 National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/. Accessed 1 August 2011
  27. 27.
    Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108(5):1405–1411PubMedCrossRefGoogle Scholar
  28. 28.
    Wagner J, Tunis S, Brown M, Ching A, Almeida R (1996) Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rozen P, Levin B (eds) Prevention and early detection of colorectal cancer. Saunders, London, pp 321–356Google Scholar
  29. 29.
    Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977–1981PubMedCrossRefGoogle Scholar
  30. 30.
    Winawer SJ, Zauber AG, O’Brien MJ et al (1993) Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 328(13):901–906PubMedCrossRefGoogle Scholar
  31. 31.
    Vasen HF, Mecklin JP, Watson P et al (1993) Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36(1):1–4PubMedCrossRefGoogle Scholar
  32. 32.
    Wong SS, Leong AP, Leong TY (2004) Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach. Stud Health Technol Inform 107(Pt 1):104–110PubMedGoogle Scholar
  33. 33.
    Department of Statistics Singapore (2011) Key annual indicators. http://www.singstat.gov.sg/stats/keyind.html. Accessed 1 August 2011
  34. 34.
    Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford medical publications, 3rd edn. Oxford University Press, OxfordGoogle Scholar
  35. 35.
    Making choices in health: WHO guide to cost-effectiveness analysis (2003). World Health Organization, GenevaGoogle Scholar
  36. 36.
    Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRefGoogle Scholar
  37. 37.
    Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRefGoogle Scholar
  38. 38.
    Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ (2000) Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 24(2):137–142PubMedGoogle Scholar
  39. 39.
    Bourne TH, Whitehead MI, Campbell S et al (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43(2):92–97PubMedCrossRefGoogle Scholar
  40. 40.
    Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH (1997) Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176(2):377–380PubMedCrossRefGoogle Scholar
  41. 41.
    Langer RD, Pierce JJ, O’Hanlan KA et al (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337(25):1792–1798PubMedCrossRefGoogle Scholar
  42. 42.
    Lanspa SJ, Lynch HT, Smyrk TC et al (1990) Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program. Gastroenterology 98(5 Pt 1):1117–1122PubMedGoogle Scholar
  43. 43.
    Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29(3):160–164PubMedCrossRefGoogle Scholar
  44. 44.
    Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29(12):849–853PubMedCrossRefGoogle Scholar
  45. 45.
    Ministry of Health Singapore (2007) National health surveillance survey 2007. http://www.moh.gov.sg/mohcorp/uploadedFiles/Publications/Reports/2009/nhss2007.pdf. Accessed 1 August 2011
  46. 46.
    Van Bebber SL, Liang S-Y, Phillips KA et al (2007) Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Pers Med 4(3):341–350CrossRefGoogle Scholar
  47. 47.
    Esplen MJ, Madlensky L, Butler K et al (2001) Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 103(1):9–15PubMedCrossRefGoogle Scholar
  48. 48.
    Kolata G (1998) Genetic testing falls short of public embrace. The New York times, 27 March 1998, p A16Google Scholar
  49. 49.
    Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281(17):1618–1622PubMedCrossRefGoogle Scholar
  50. 50.
    Davey A, Rostant K, Harrop K, Goldblatt J, O’Leary P (2005) Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service. J Genet Couns 14(3):197–206PubMedCrossRefGoogle Scholar
  51. 51.
    Winawer SJ, Fletcher RH, Miller L et al (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112(2):594–642PubMedCrossRefGoogle Scholar
  52. 52.
    Sonnenberg A, Delco F, Inadomi JM (2000) Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133(8):573–584PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Vivian Wei Wang
    • 1
  • Poh Koon Koh
    • 2
  • Wai Leng Chow
    • 1
  • Jeremy Fung Yen Lim
    • 3
  1. 1.Center for Health Services ResearchSingapore Health Services Pte LtdSingaporeSingapore
  2. 2.Department of Colorectal SurgerySingapore General HospitalSingaporeSingapore
  3. 3.Lien Centre for Palliative CareDuke-NUS Graduate Medical School SingaporeSingaporeSingapore

Personalised recommendations